



Announcement Summary

Entity name

CLINUVEL PHARMACEUTICALS LIMITED

Date of this announcement

Thursday May 07, 2026

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
CUVAK	PERFORMANCE RIGHTS	887,956	30/04/2026

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

CLINUVEL PHARMACEUTICALS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ABN

Registration number

88089644119

1.3 ASX issuer code

CUV

1.4 The announcement is

New announcement

1.5 Date of this announcement

7/5/2026



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")

For personal use only



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description

CUVAK : PERFORMANCE RIGHTS

Date the +securities the subject of this notification were issued

30/4/2026

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
Lachlan Hay	Lachlan Hay	20,000
Dennis Wright	Dennis Wright	20,000
Peter Vaughan	JABEC Investment Family Trust	20,000

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

<https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02718497-3A627242&v=7bc42bd11d853ed5e8c28f2ffcd6a069ee5cd6b4>

Any other information the entity wishes to provide about the +securities the subject of this notification

Unlisted performance rights issued to staff of the CLINUVEL group of companies. Each Performance Right has a nil exercise price and an expiry date of 31 December 2026.

Each Performance Rights entitles the holder to receive one fully paid ordinary share in CLINUVEL, subject to achieving certain time-based and company performance-based vesting conditions. Unless the Board determines otherwise, each staff member must be employed by CLINUVEL on the expiry date in order to exercise those Performance Rights who have otherwise met their performance condition.

The issue of performance rights is for the maximum amount achievable under the plan to employees (excluding the CEO). Historically, 60-65% of KPI's have been achieved under the plan.

Issue details**Number of +securities**

887,956



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

ASX +security code and description	Total number of +securities on issue
CUV : ORDINARY FULLY PAID	50,427,898

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
CUVAK : PERFORMANCE RIGHTS	1,014,181



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13